文献速递肝病

ABIDE:非酒精性脂肪性肝相关肝硬化患者肝功能失代偿的准确预测模型

ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis.
PubMed 文献 · Hepatology · 2021-04-19

研究回顾性构建并验证了ABIDE模型,用于预测非酒精性脂肪性肝病(NAFLD)合并代偿期肝硬化患者的肝功能失代偿。推导队列299例,验证队列244例,中位随访5.6年和5.4年。ABIDE模型5年预测准确性良好(推导队列tAUC 0.80,验证队列0.78),显著优于现有模型。

要点

  • ABIDE模型由AST/ALT比值、胆红素、INR、2型糖尿病和食管静脉曲张组成。
  • 评分≥4.1者较<4.1者失代偿风险更高(subhazard ratio 6.7,95%CI 4.0-11.2,P<0.001)。
  • ABIDE模型5年tAUC在推导队列为0.80,验证队列为0.78,优于NFS、FIB-4、MELD、CTP和ALBI-FIB-4。

核心结论

  • 在NAFLD合并代偿期肝硬化患者中,ABIDE这一基于常规临床指标的预测模型可预测未来肝功能失代偿。

研究设计与样本

  • 回顾性开发并验证预测模型,推导队列为国际队列299例经活检证实的NAFLD合并代偿期肝硬化患者,验证队列为美国244例经活检证实的NAFLD肝硬化患者。
  • 使用竞争风险多变量回归和Akaike/贝叶斯信息准则构建模型,并与NAFLD纤维化评分(NFS)、FIB-4、MELD、CTP和ALBI-FIB-4评分采用时间依赖AUC(tAUC)分析比较预测准确性。

主要发现

  • 推导队列中位随访5.6年(范围2.4-14.1),验证队列中位随访5.4年(范围1.5-13.8),分别有81例和132例发生肝功能失代偿。
  • 推导队列中,肝功能失代偿的独立预测因素为AST/ALT比值、胆红素、INR、2型糖尿病和食管静脉曲张,组合为ABIDE模型。
  • ABIDE评分≥4.1者较评分<4.1者失代偿风险更高(subhazard ratio 6.7;95%CI 4.0-11.2;P<0.001),5年累积发生率更高(37% vs 6%,P<0.001),平均至失代偿时间更短(3.8年 vs 6.7年,P<0.001)。
  • ABIDE模型5年预测准确性在推导队列tAUC为0.80(95%CI 0.73-0.84),验证队列为0.78(95%CI 0.74-0.81)。
  • ABIDE模型5年预测准确性显著优于NFS(0.72)、FIB-4(0.74)、MELD(0.69)、CTP(0.72)和ALBI-FIB-4(0.73)(均P<0.001)。

关键数值与推荐

  • ABIDE模型包含AST/ALT比值、胆红素、INR、2型糖尿病和食管静脉曲张。
  • ABIDE评分≥4.1为高风险阈值,对应失代偿subhazard ratio 6.7(95%CI 4.0-11.2,P<0.001)、5年累积发生率37% vs 6%(P<0.001)、平均至失代偿时间3.8年 vs 6.7年(P<0.001)。
  • ABIDE模型5年tAUC在推导队列为0.80(95%CI 0.73-0.84),验证队列为0.78(95%CI 0.74-0.81)。
  • 对照模型5年tAUC:NFS 0.72、FIB-4 0.74、MELD 0.69、CTP 0.72、ALBI-FIB-4 0.73,ABIDE与各模型比较均P<0.001。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) is an increasingly important cause of liver cirrhosis and subsequent complications. We retrospectively developed and validated a model to predict hepatic decompensation in patients with NAFLD and cirrhosis and compared this with currently available models. APPROACH AND RESULTS: Baseline variables from an international cohort of 299 patients with biopsy-proven NAFLD with compensated cirrhosis were examined to construct a model using competing risk multivariate regression and Akaike/Bayesian information criteria. Validation was performed in 244 patients with biopsy-proven NAFLD cirrhosis from the United States. Prognostic accuracy was compared with the NAFLD fibrosis score (NFS), fibrosis-4 (FIB-4), Model for End-Stage Liver Disease (MELD), Child-Turcotte-Pugh (CTP), and albumin-bilirubin (ALBI)-FIB-4 score using time-dependent area under the curve (tAUC) analysis. During a median follow-up of 5.6 years (range 2.4-14.1) and 5.4 years (range 1.5-13.8), hepatic decompensation occurred in 81 and 132 patients in the derivation and validation cohorts, respectively. In the derivation cohort, independent predictors of hepatic decompensation (Aspartate aminotransferase/alanine aminotransferase ratio, Bilirubin, International normalized ratio, type 2 Diabetes, and Esophageal varices) were combined into the ABIDE model. Patients with a score ≥4.1 compared with those with a score <4.1 had a higher risk of decompensation (subhazard ratio, 6.7; 95% confidence interval [CI], 4.0-11.2; P < 0.001), a greater 5-year cumulative incidence (37% vs. 6%, P < 0.001), and shorter mean duration to decompensation (3.8 vs 6.7 years, P < 0.001). The accuracy of the ABIDE model at 5 years was good in the derivation (tAUC, 0.80; 95% CI, 0.73-0.84) and validation cohorts (0.78; 95% CI, 0.74-0.81) and was significantly more accurate than the NFS (0.72), FIB-4 (0.74), MELD (0.69), CTP (0.72), and ALBI-FIB-4 (0.73) (all P < 0.001). CONCLUSIONS: In patients with NAFLD and compensated cirrhosis, ABIDE, a predictive model of routine clinical measures, predicts future hepatic decompensation.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Calzadilla-Bertot L, Vilar-Gomez E, Wong VW, et al. ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. Hepatology. 2021. PMID: 32978796. doi:10.1002/hep.31576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。